Home > Healthcare > Medical Devices > Diagnostic Devices > Heart Failure POC and LOC Devices Market

Heart Failure POC and LOC Devices Market Size

  • Report ID: GMI9564
  • Published Date: May 2024
  • Report Format: PDF

Heart Failure POC and LOC Devices Market Size

Heart failure POC and LOC Devices Market size was valued at around USD 91.7 million in 2023 and is estimated to grow at 16.4% CAGR from 2024 to 2032. Heart failure POC (Point-of-Care) and LOC (Low-oxygen concentration) devices are medical devices designed to assist in the diagnosis, monitoring, and management of heart failure, a chronic condition characterized by the heart's inability to pump blood effectively. These devices are intended for use at the point of care, such as clinics, hospitals, or home settings, to provide rapid and convenient assessment of heart function and oxygenation status.

 

The advancement in diagnostic technologies is a significant driver for the heart failure POC and LOC devices market. For instance, National Institutes of Health, in 2023, paper-based microfluidics offers inherent microfluidic benefits along with the performance of lateral flow strips. Further, chemiluminescence techniques on paper microfluidics can perform multiplexed analysis of antibodies like cardiac troponin I (cTnI), heart-type fatty acid-binding protein (H-FABP), and copeptin for acute myocardial infarction diagnosis.
 

Moreover, increasing use of heart pump devices (market size is estimated to account for USD 9.2 billion by the end of year 2032), rising adoption of prosthetic heart valves, advancement in structural heart devices, rising healthcare expenditure globally, government initiatives and funding, and increasing education & awareness, are the stretching factors advancing the growth of the market.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Heart failure POC and LOC devices industry size was valued at USD 91.7 million in 2023 and is estimated to grow at 16.4% CAGR from 2024 to 2032, driven by advancements in diagnostic technologies.

The proteomic testing segment in the heart market is estimated to record USD 155.9 million by 2032, owing to its vitality in biomarker discovery and validation for heart failure and CVD.

U.S. heart failure POC and LOC devices market held a decent share in 2023 and is anticipated to grow at 16% CAGR during 2024-2032, owing to the significant burden of heart failure and CVD, with millions of individuals affected by these conditions.

Abaxis, Inc., Abbott Laboratories, Becton, Dickinson, and Company, bioM

Heart Failure POC and LOC Devices Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 221
  • Countries covered: 23
  • Pages: 160
 Download Free Sample